Limitless Consulting Warns Employer Health Plans: Executive Order 14411 Changes International Pharmacy Sourcing

Limitless Consulting

EO White Paper discussing the impact on customs and, ultimately, international sourcing of medications.

Timeline of events and impact of the EO on international sourcing of medications.

Limitless offers employers a complimentary international pharmacy sourcing review and a repriced estimate across nine sourcing channels.

CO, UNITED STATES, September 9, 2026 /EINPresswire.com/ -- Limitless Consulting Group, LLC, the veteran-founded healthcare consulting firm behind the Pharmacy Stewardship Program^®, has published a white paper, Executive Order 14411: International Sourcing Overview and Impact 2026, together with a short film, on what the order means for self-funded employer health plans whose members receive medications through an international sourcing vendor. The firm is also offering employers a complimentary review of their current sourcing program, returned within 1 to 3 business days.

Executive Order 14411, Strengthening Customs Enforcement, was signed 3 June 2026 (91 Fed. Reg. 35125). It has nothing to say about drug prices or importation of medications. What it changes is who may act as the importer of record, the party that signs for a parcel at the border, whether a bond must stand behind every entry, and whether a foreign importer may still use the simplified informal entry that carried most direct to member parcels. The 180-day provisions on importer eligibility and vetting are due 30 November 2026.

A second authority reaches the same parcels. On 24 June 2026, US Customs and Border Protection published an interim final rule that suspended the de minimis exemption for international mail. The new postal informal entry process it created excludes merchandise subject to partner government agency requirements as of 22 October 2026. FDA is a partner government agency, and human drugs carry FDA data requirements at entry, so prescription medications fall inside that exclusion.

Neither document mentions a health plan, so most plan sponsors have not heard of either. International sourcing depends on a foreign pharmacy shipping a filled prescription to a US member as a low value parcel. Each provision attaches a fixed cost to that parcel, unrelated to the price of the drug, and adds days between the fill and the member's door. A $40 generic now carries the same customs cost as a $4,000 brand, so the change lands hardest on the low cost lines in a sourcing program. A member on a 90 day fill has one refill between now and 30 November, and the timing of that refill now depends on how the vendor's parcels enter the country.

The white paper describes 3 ways the industry moves a parcel. In the first, the foreign pharmacy or a consolidator is the importer of record. In the second, a US entity owned by the foreign operator signs for the parcel. In the third, the member is the importer and a vendor coordinates the shipment. The first 2 have to change how the parcel enters. The third changes in cost and in timeline, but its structure holds. The paper also carries 10 questions a plan sponsor should put to its current vendor in writing.

"Executive Order 14411 changes the playing field and will likely drive significant consolidation across what has grown into a billion-dollar market," said Louis M. Gallucci, GBDS, Chief Executive Officer of Limitless Consulting Group. "Our team felt compelled to make this video because we care about what happens next. We care about the consultants and brokers we support, the TPAs and PBMs we partner with, and most importantly, the employers and plan members who will ultimately be impacted by the changes now taking shape in the international pharmacy sourcing market."

Employers and consultants are asking Limitless how to keep the saving on high-cost medications while much of the market scramble for solutions and a sourcing vendor works through the new entry rules. The Pharmacy Stewardship Program^® prices every medication on a plan across 9 optimized sourcing channels and identifies the lowest net cost route available to each member. Limitless does not source, import or dispense medications; licensed vendors hold every sourcing relationship and every shipping obligation. Where a vendor's parcel route changes, the same drug often has a domestic route, whether a biosimilar, a cash price, a manufacturer or charitable foundation program, a 340B pharmacy or a group purchasing contract.

One of those domestic routes is the published Cost Plus Drugs list. Limitless prices a plan's claims against the published Cost Plus Drugs and TrumpRx lists to find where a published price undercuts what the plan paid on the same fill. The pharmacy benefit manager, the network and the formulary stay in place, and the plan document is not amended. Limitless is paid out of the documented saving, and the fee is disclosed. The list is strongest on generics and a defined set of biosimilars, where a plan paying more than $10,000 a fill for a branded biologic can be looking at a published price of several hundred dollars.

"This is exactly why we built the Pharmacy Stewardship Program around multiple sourcing channels rather than dependence on any single vendor or any single market," Gallucci said. "If an employer's existing international sourcing model is affected, our job is to create a soft landing. We can take the medications being sourced today, understand the savings being generated today, and determine where those members should go next."

The complimentary review starts with the vendor's most recent savings report or a list of the plan's 25 highest cost medications. Limitless prices every line across all 9 channels and shows what is preserved, what moves to a domestic route, and what changes for the member. Where the current vendor's price is better on a line, the analysis says so. The employer's benefits consultant leads the engagement. There is no fee and no obligation.

"A plan sponsor has about one quarter to find out whether its vendor can still deliver, and the January renewals will be the first plan year run entirely under the new entry rules," said Mike McLain, FACHE, MHA, MBA, Co-Founder and President. "The time to ask a vendor how its parcels will enter the country is now, while there is still a full refill cycle left before 30 November."

To request the white paper or the complimentary review, visit https://limitlessrxsolutions.com/compliance-safety, email Support@LimitlessRxSolutions.com or call (719) 789-2268.

Claire Morgan
Limitless Consulting
Support@LimitlessRxSolutions.com
Visit us on social media:
LinkedIn

Limitless Consulting Warns Employer Health Plans: Executive Order 14411 Changes International Pharmacy Sourcing